ClinicalTrials.gg
RecruitingNCT06263465Updated May 14, 2024

Precision Vaginal Microbiome Transplantation in Women With Bacterial Vaginosis

An interventional study of Lactobacillus cispatus and placebo in Bacterial Vaginosis, sponsored by Zhujiang Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Zhujiang Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Vaginosis, Bacterial with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Vaginosis, Bacterial · China.

Planned enrollment
9th of 16
120 · median 123
Started
2024
with 1 other
No phase
2 of 16
1 open now
Registered
8th of 16
by date

Among the 16 studies in Vaginosis, Bacterial with a site in China, this one is the 9th largest by planned enrollment, is one of 2 that started in 2024, is one of 2 with no phase, and was the 8th registered.

Vaginosis, Bacterial

240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.

Browse Vaginosis, Bacterial studies →

Open to participants now

6 of the 16 studies in Vaginosis, Bacterial with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 23 Vaginosis, Bacterial studies recruiting now, 7 (30%) set no upper age limit and 16 (70%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Vaginosis, Bacterial with a site in China, or all of them as a file.
02

Study summary

The aim of this study was to explore the efficacy and safety of a new vaginal microbiome transplantation technique, using Lactobacillus cispatus from healthy donors as a treatment of bacterial vaginosis.

Read the detailed description

The volunteers will be recruited from the women who come to the hospital to do the bacterial vaginosis test. After being informed about the potential risks, each volunteer giving written informed consent will be asked to complete a questionnaire.

Then, posterior fornix of vagina secretions will be taken from each volunteer to perform 16S rRNA gene sequencing microecology assessment , Clue cell detection and amine test.

After 2weeks ,1 month ,3 months,6 months,12 monthssince the entry, each volunteer will be asked to go back to research center to do the same sampling and examination as previously did in entry.

03

Conditions studied

  • Bacterial Vaginosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. History of sexual behaviour 2.18-55 years old 3. Women were diagnosed as bacterial vaginosis

Exclusion criteria

Exclusion Criteria:

  1. During pregnancy, or within 8 weeks after delivery;
  2. presence of systemic diseases (such as SLE, malignant tumors, etc.)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Lactobacillus cispatus

    10\^9 cfu,5 days

    Other: Lactobacillus cispatus

  • Placebo comparator
    Placebo

    0 cfu,5 days

    Other: placebo

Interventions

  • OtherLactobacillus cispatus

    10\^9 cfu,5 days

  • Otherplacebo

    0 cfu,5 days

06

What researchers measure

Primary outcomes

  1. BV recurrence rate

    Primary Outcome Measure

    Time frame: month 12

Secondary outcomes

  1. vaginal secretions 16s rRNA gene sequencing

    Secondary Outcome Measures

    Time frame: 2 weeks,month 1,month 3、month 6、month 12

  2. BV recurrence rate

    Secondary Outcome Measures

    Time frame: 2 weeks,month 1,month 3、month 6

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jul 2025, 15 months after the start.

Of 52 interventional studies with no phase under Vaginosis, Bacterial, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 56. This study's planned 15 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Feb 16, 2024
StartActual
Mar 18, 2024
Primary completionEst.
Jul 1, 2025
CompletionEst.
Dec 31, 2025
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06263465
Lead sponsor
Zhujiang Hospital
Collaborators
ZhuHai Hospital
Responsible party
Hongwei Zhou (Professor, Zhujiang Hospital) — Principal investigator
First posted
Feb 16, 2024
Start date
Mar 18, 2024
Primary completion
Jul 1, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
May 14, 2024

Study contacts

Muxuan Chen, Doctor
Contact
muxuanchen@126.com
+8613580561916
Hongwei Zhou, Professor
principal investigator · Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion